Immunoneutralization of agmatine sensitizes mice to micro-opioid receptor tolerance.
Systemically or centrally administered agmatine (decarboxylated arginine) prevents, moderates, or reverses opioid-induced tolerance and self-administration, inflammatory and neuropathic pain, and sequelae associated with ischemia and spinal cord injury in rodents. These behavioral models invoke the N-methyl-D-aspartate (NMDA) receptor/nitric-oxide synthase cascade. Agmatine (AG) antagonizes the NMDA receptor and inhibits nitric-oxide synthase in vitro and in vivo, which may explain its effect in models of neural plasticity. Agmatine has been detected biochemically and immunohistochemically in the central nervous system. Consequently, it is conceivable that agmatine operates in an anti-glutamatergic manner in vivo; the role of endogenous agmatine in the central nervous system remains minimally defined. The current study used an immunoneutralization strategy to evaluate the effect of sequestration of endogenous agmatine in acute opioid analgesic tolerance in mice. First, intrathecal pretreatment with an anti-AG IgG (but not normal IgG) reversed an established pharmacological effect of intrathecal agmatine: antagonism of NMDA-evoked behavior. This result justified the use of anti-AG IgG to sequester endogenous agmatine in vivo. Second, intrathecal pretreatment with the anti-AG IgG sensitized mice to induction of acute spinal tolerance of two micro-opioid receptor-selective agonists, [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin and endomorphin-2. A lower dose of either agonist that, under normal conditions, produces moderate or no tolerance was tolerance-inducing after intrathecal pretreatment of anti-AG IgG (but not normal IgG). The effect of the anti-AG IgG lasted for at least 24 h in both NMDA-evoked behavior and the acute opioid tolerance. These results suggest that endogenous spinal agmatine may moderate glutamate-dependent neuroplasticity.
Wade
Carrie L
CL
Departments of Pharmaceutics, University of Minnesota, Minneapolis, Minnesota 55455, USA. carfair@umn.edu
Eskridge
Lori L
LL
Nguyen
H Oanh X
HO
Kitto
Kelley F
KF
Stone
Laura S
LS
Wilcox
George
G
Fairbanks
Carolyn A
CA
D000376:Agmatine / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology*; D001120:Arginine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D018690:Excitatory Amino Acid Agonists; D006168:Guinea Pigs; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000494:pharmacology; D007150:Immunohistochemistry; D007278:Injections, Spinal; D008297:Male; D051379:Mice; D016202:N-Methylaspartate; D009842:Oligopeptides / Q000494:pharmacology; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000187:drug effects*; D013116:Spinal Cord / Q000187:drug effects
D000701:Analgesics, Opioid; D019138:Antibodies, Blocking; D018690:Excitatory Amino Acid Agonists; D007074:Immunoglobulin G; D009842:Oligopeptides; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C105294:endomorphin 2; D016202:N-Methylaspartate; D000376:Agmatine; D001120:Arginine
Science. 1979 Oct 5;206(4414):89-91
39340
J Pharmacol Exp Ther. 2000 Feb;292(2):576-83
10640294
Brain Res. 1981 May 4;211(2):379-86
6165431
Neuroreport. 1997 Sep 29;8(14):3131-5
9331928
J Pharmacol Exp Ther. 1997 Sep;282(3):1408-17
9316854
J Neurochem. 1997 Dec;69(6):2421-6
9375674
Nature. 1997 Apr 3;386(6624):499-502
9087409
Eur J Pharmacol. 1980 Oct 17;67(2-3):313-6
6893963
Br J Pharmacol. 1994 Mar;111(3):703-10
7912623
Neurosci Lett. 1991 Oct 28;132(1):29-32
1787914
Neurosci Lett. 2005 Dec 30;390(3):129-33
16125317
Science. 1994 Feb 18;263(5149):966-9
7906055
J Neurochem. 2007 Sep;102(6):1738-1748
17539920
Neuroreport. 1995 Oct 2;6(14):1897-900
8547593
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10584-9
10984543
Pharmacol Biochem Behav. 2002 Jul;72(4):873-80
12062577
Eur J Pharmacol. 1996 Jan 18;296(1):17-22
8720472
Brain Res. 1998 Mar 16;787(1):1-14
9518530
Brain Res. 2002 Oct 11;952(1):71-7
12363406
J Pharmacol Exp Ther. 2001 Aug;298(2):592-7
11454920
Neurosci Lett. 2000 Dec 22;296(2-3):97-100
11108990
Mol Pharmacol. 2001 Jan;59(1):24-9
11125020
Brain Res. 1985 Jul 29;339(2):285-93
4027627
J Pharmacol Exp Ther. 1990 Dec;255(3):1001-7
2148185
Nature. 1984 Mar 15-21;308(5956):278-80
6322011
J Pharmacol Exp Ther. 2005 Sep;314(3):1226-33
15933157
Science. 1992 Dec 18;258(5090):1946-9
1470919
Neuroreport. 2000 Sep 28;11(14):3203-7
11043549
J Pharmacol Exp Ther. 1999 Feb;288(2):544-9
9918557
Adv Pharmacol. 1998;42:645-9
9327985
Eur J Pharmacol. 2008 Jun 10;587(1-3):135-40
18495108
Naunyn Schmiedebergs Arch Pharmacol. 1995 Jan;351(1):10-6
7715734
J Neurochem. 1996 Oct;67(4):1761-5
8858963
Biochem J. 1996 May 15;316 ( Pt 1):247-9
8645212
Neuroreport. 2006 Jan 23;17(1):13-7
16361942
J Neurochem. 2007 Jan;100(1):132-41
17227436
Neuroreport. 1994 Dec 20;5(18):2601-5
7696612
Ann N Y Acad Sci. 2003 Dec;1009:82-105
15028573
J Pharmacol Exp Ther. 1996 May;277(2):784-8
8627559